$CLPT

Richards Timothy T. sold $66K of CLPT

Richards Timothy T. sold 5,415 shares of ClearPoint Neuro, Inc. (CLPT) at $12.17 on 2026-06-01.

Original reporting
SEC EDGAR · Richards Timothy T.
Published Jun 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLPT
Neutral
low confidence
Mentioned
$CLPT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

Insider selling can influence retail sentiment, but without additional company-specific developments, the trading signal is typically weak.

02

Market read

A new Form 4 reports an insider open-market sale at $12.17, offering limited incremental information for trading decisions.

03

What to watch

No context on total insider holdings over time, whether other insiders sold/bought, or whether the sale was part of a broader pattern; also no 10b5-1 plan is stated.

Relevance 3/10Novelty 4/10Timing: filed 2026-06-02, sale dated 2026-06-01

Background

The article is an SEC Form 4 insider transaction disclosure for ClearPoint Neuro, Inc. (CLPT).

Company-level read

Ticker impact

$CLPTNeutralLow confidence
Context

ClearPoint Neuro director Timothy T. Richards sold 5,415 shares at $12.17 on 2026-06-01, per a new SEC Form 4 filed 2026-06-02.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond typical insider-selling noise.

Evidence & confidence

The filing is a primary-source Form 4, but the article provides only the sale size and price, with no accompanying company news, guidance, or material corporate event.

Market effects

No sector read-through is provided; this appears company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification, taxes, or pre-existing personal liquidity needs, so it may not reflect negative company fundamentals.

Key entities

  • ClearPoint Neuro, Inc.

    Company whose director sold shares, disclosed via SEC Form 4.

  • Timothy T. Richards

    Director who executed an open-market sale of 5,415 shares.

Related articles

$CLPTMed

ClearPoint Neuro, Inc. (CLPT): Results of Operations and Financial Condition

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, In